secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001104659-23-005489
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health approves 1-for-75 reverse stock split; Phase 3 crofelemer trial to complete Q2 2023
--------------------------------------------------------------------------------

- Reverse stock split 1-for-75 effective Jan 23, 2023; new CUSIP 47010C706.
- All three stockholder proposals approved at Jan 20 special meeting.
- Pivotal Phase 3 OnTarget trial of crofelemer for CTD; enrollment completion expected Q2 2023.
- Proof-of-concept trial for SBS/CDD underway; potential early access programs in Europe in 2023.
- No fractional shares; cash in lieu; trading continues on Nasdaq under symbol JAGX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/tm234025d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-005489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer